Total Payments
$25,435
2024 Payments
$4,346
Companies
48
Transactions
1,326
Medicare Patients
11,522
Medicare Billing
$852,213
Payment Breakdown by Category
Food & Beverage$25,151 (98.9%)
Education$284.21 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $25,151 | 1,320 | 98.9% |
| Education | $284.21 | 6 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $4,650 | 307 | $0 (2024) |
| Janssen Biotech, Inc. | $2,648 | 124 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,282 | 113 | $0 (2024) |
| Amgen Inc. | $1,928 | 89 | $0 (2024) |
| Lilly USA, LLC | $1,767 | 82 | $0 (2024) |
| LEO Pharma Inc. | $1,698 | 81 | $0 (2024) |
| PFIZER INC. | $1,163 | 58 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $989.69 | 53 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $944.45 | 55 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $904.31 | 39 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,346 | 222 | ABBVIE INC. ($567.11) |
| 2023 | $4,583 | 216 | ABBVIE INC. ($860.05) |
| 2022 | $3,410 | 175 | ABBVIE INC. ($990.15) |
| 2021 | $3,063 | 178 | AbbVie Inc. ($670.71) |
| 2020 | $2,545 | 134 | AbbVie Inc. ($394.91) |
| 2019 | $2,957 | 167 | Novartis Pharmaceuticals Corporation ($501.62) |
| 2018 | $2,595 | 136 | Novartis Pharmaceuticals Corporation ($368.20) |
| 2017 | $1,935 | 98 | AbbVie, Inc. ($362.96) |
All Payment Transactions
1,326 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.60 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $19.70 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $4.57 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $2.81 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.41 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $8.58 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: Dermatology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $35.78 | General |
| Category: Immunology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $19.14 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $28.02 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: DERMATOLOGY | ||||||
| 11/26/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Dermatology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.58 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $9.67 | General |
| Category: Immunology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $29.56 | General |
| Category: Immunology | ||||||
| 11/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,154 | 2,829 | $367,190 | $170,759 |
| 2022 | 21 | 2,301 | 3,194 | $392,367 | $169,082 |
| 2021 | 23 | 3,186 | 4,532 | $529,263 | $239,134 |
| 2020 | 28 | 3,881 | 5,447 | $590,185 | $273,238 |
Total Patients
11,522
Total Services
16,002
Medicare Billing
$852,213
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 579 | 683 | $95,644 | $43,882 | 45.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 291 | 326 | $58,538 | $27,767 | 47.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 151 | 198 | $52,718 | $26,644 | 50.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 254 | 296 | $47,497 | $20,824 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 131 | $25,958 | $12,683 | 48.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 204 | 228 | $24,069 | $8,858 | 36.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 129 | 150 | $13,188 | $5,967 | 45.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 64 | 64 | $11,117 | $5,145 | 46.3% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 42 | 44 | $8,678 | $4,311 | 49.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 50 | 72 | $5,706 | $3,057 | 53.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $5,067 | $2,334 | 46.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 139 | 427 | $4,517 | $2,318 | 51.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $4,378 | $2,099 | 47.9% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 11 | 11 | $3,561 | $1,903 | 53.4% |
| 10040 | Acne surgery | Office | 2023 | 14 | 14 | $2,570 | $1,324 | 51.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 17 | 17 | $1,911 | $795.18 | 41.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 15 | 16 | $1,437 | $527.78 | 36.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 22 | $484.35 | $247.17 | 51.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 30 | 95 | $152.66 | $73.19 | 47.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 703 | 847 | $120,723 | $51,904 | 43.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 272 | 310 | $56,442 | $26,715 | 47.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 142 | 204 | $55,013 | $26,271 | 47.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 211 | 235 | $38,719 | $16,096 | 41.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 130 | 139 | $27,925 | $10,313 | 36.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 240 | 273 | $29,255 | $10,282 | 35.1% |
About Dr. David Pomerantz, MD
Dr. David Pomerantz, MD is a Dermatology healthcare provider based in Pawtucket, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972529832.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Pomerantz, MD has received a total of $25,435 in payments from pharmaceutical and medical device companies, with $4,346 received in 2024. These payments were reported across 1,326 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($25,151).
As a Medicare-enrolled provider, Pomerantz has provided services to 11,522 Medicare beneficiaries, totaling 16,002 services with total Medicare billing of $852,213. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Pawtucket, RI
- Active Since 07/14/2006
- Last Updated 04/19/2013
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1972529832
Products in Payments
- TREMFYA (Drug) $1,818
- COSENTYX (Biological) $1,732
- TALTZ (Drug) $1,609
- SKYRIZI (Biological) $1,484
- DUPIXENT (Biological) $1,383
- Otezla (Drug) $1,317
- RINVOQ (Biological) $1,137
- EUCRISA (Drug) $1,085
- Humira (Biological) $963.36
- ADBRY (Biological) $870.67
- HUMIRA (Biological) $861.97
- ENSTILAR (Drug) $785.55
- Sotyktu (Drug) $765.94
- Enbrel (Biological) $653.29
- Cimzia (Drug) $620.38
- ILUMYA (Biological) $490.85
- VTAMA (Drug) $473.88
- REMICADE (Biological) $468.35
- Tremfya (Drug) $403.49
- DUOBRII (Drug) $321.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.